21:17 , Nov 10, 2017 |  BC Week In Review  |  Clinical News

Vidac reports Phase IIa data for VDA-1102 in actinic keratosis

Vidac Pharma Ltd. (Jerusalem, Israel) said 10% VDA-1102 ointment missed the primary endpoint of reducing the mean number of actinic keratosis (AK) lesions on the face or scalp combined from baseline to day 56 vs....
20:34 , Jun 1, 2017 |  BC Innovations  |  Tools & Techniques

WuXi ex machina

Since its acquisition two years ago by New WuXi Life Science Ltd., WuXi NextCode Genomics Inc. has been busy building out its artificial intelligence (AI) capabilities and test driving them via its expanding network of...
07:00 , Jul 11, 2016 |  BioCentury  |  Finance

Advising Israel

BC Staff  A new Israeli VC fund is leveraging a broad base of biopharma advisers to give its portfolio companies an advantage in development, partnering and commercialization activities. Israel Biotech Fund is raising its first...
01:06 , Jul 1, 2016 |  BC Extra  |  Financial News

Vidac raises $9M series A round

Vidac Pharma (Jerusalem, Israel) raised $9 million in a series A financing led by new investor Israel Biotech Fund. Existing investors including Mivtach Shamir Holdings also participated. The company's VDA-1102 ointment is in a Phase...
07:00 , Mar 16, 2015 |  BC Week In Review  |  Company News

TransTech, Calithera Biosciences deal

TransTech granted cancer company Calithera exclusive, worldwide rights to develop and commercialize a portfolio of preclinical small molecule hexokinase 2 (HK2) inhibitors. TransTech will receive $600,000 up front and is eligible to receive up...
07:00 , Oct 13, 2011 |  BC Innovations  |  Strategy

Lilly's opening moves

When Eli Lilly and Co. launched its Phenotypic Drug Discovery Initiative in 2009, its goal was to apply a crowdsourcing approach to finding new small molecules from external investigators that fit the company's core disease...
08:00 , Feb 17, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/ pathway Summary Licensing status Publication and contact information Cancer Glioblastoma multiforme (GBM) Hexokinase 2 (HK2) Studies in mice and in patient samples suggest that inhibiting...
07:00 , Jun 29, 2009 |  BC Week In Review  |  Company News

Med Discovery, University of Lausanne deal

Med Discovery received exclusive, worldwide rights to the university's peptides derived from RAS p21 protein activator GTPase activating protein 1 ( RASA1, RASGAP, p120GAP), which have been shown to enhance the effect...